Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate tabelecleucel, formerly ATA129, in Phase 3 for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline also encompasses an investigational candidate in Phase 2 clinical studies for refractory CMV infection; and two Phase 1 candidates for the treatment of MS; and a Phase 1 for the treatment of residual or relapsed leukemia after HCT, and for T-cell depleted HCT for patients with relapsed or refractory multiple myeloma plasma cell leukemia (PCL). It has presence in the US, Cayman Islands, Ireland, and Switzerland. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Partnerships 21
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Licensing Agreements 23
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Equity Offering 29
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc - Key Competitors 39
Atara Biotherapeutics Inc - Key Employees 40
Atara Biotherapeutics Inc - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Nov 06, 2018: Atara Biotherapeutics announces third quarter 2018 financial results and recent operational progress 43
Aug 01, 2018: Atara Biotherapeutics announces second quarter 2018 financial results and recent operational progress 45
May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress 48
Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress 50
Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights 54
Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights 56
May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights 58
Mar 09, 2017: Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 60
Corporate Communications 61
Sep 11, 2018: Atara Biotherapeutics names Roy Baynes as Board Director 61
Jun 07, 2018: Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer 62
May 07, 2018: Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development 63
Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 64
Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 65
May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head 66
Product News 67
09/11/2017: Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 67
04/03/2017: Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer 68
Product Approvals 69
Jan 03, 2017: Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) 69
Clinical Trials 70
Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 70
Jan 02, 2018: Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 71
Dec 29, 2017: Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 72
Dec 11, 2017: Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder 74
Nov 01, 2017: Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers 76
Oct 25, 2017: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 78
Oct 19, 2017: Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis 80
Oct 16, 2017: Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis 81
Aug 22, 2017: Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer 82
Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 83
May 10, 2017: Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team 84
Apr 20, 2017: Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis at the American Academy of Neurology Annual Meeting 2017 85
Mar 17, 2017: Atara Bio Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis 87
Mar 09, 2017: Atara Bio Provides Update on ATA-129 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List Of Tables


Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc, Key Competitors 39
Atara Biotherapeutics Inc, Key Employees 40
Atara Biotherapeutics Inc, Other Locations 41
Atara Biotherapeutics Inc, Subsidiaries 41

List Of Figures


Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its

USD 250 View Report

Atara Biotherapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Atara Biotherapeutics Inc Company Profile is a detailed strategic and analytical report on Atara Biotherapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Stealth BioTherapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Stealth BioTherapeutics Inc (Stealth), formerly Stealth Peptides Inc is a clinical stage biopharmaceutical company that develops therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available